mFOLFIRINOX联合雷莫西尤单抗对比mFOLFIRINOX联合安慰剂治疗晚期胰腺癌患者的II期随机双盲研究(HCRN GI14-198)
这项II期随机双盲多中心安慰剂对照试验比较mFOLFIRINOX联合雷莫西尤单抗(A组)与联合安慰剂(B组)一线治疗复发/转移性胰腺导管腺癌。共入组86例,82例可评估(A组42例,B组40例)。9个月无进展生存率A组25.1%对B组35.0%(p=0.322),中位无进展生存期A组5.6个月对B组6.7个月,中位总生存期A组10.3个月对B组9.7个月(p=0.094),疾病缓解率A组17.7%对B组22.6%。结论:加用雷莫西尤单抗未显著影响无进展生存期或总生存期,联合方案耐受良好。
要点
- 9个月无进展生存率A组25.1%对B组35.0%(p=0.322),差异未达统计学显著。
- 中位无进展生存期A组5.6个月对B组6.7个月,中位总生存期A组10.3个月对B组9.7个月(p=0.094)。
- 疾病缓解率A组17.7%对B组22.6%,mFOLFIRINOX联合雷莫西尤单抗耐受良好。
核心结论
- 在mFOLFIRINOX基础上加用雷莫西尤单抗未显著影响转移性胰腺导管腺癌患者的无进展生存期或总生存期,联合方案耐受良好。
研究设计与样本
- II期随机、多中心、安慰剂对照、双盲试验,纳入复发/转移性胰腺导管腺癌患者,随机分配至mFOLFIRINOX联合雷莫西尤单抗组(A组)或mFOLFIRINOX联合安慰剂组(B组)。
- 共入组86例,82例可评估(A组42例对B组40例),主要终点为9个月无进展生存率,次要终点包括总生存期、缓解率和毒性评估。
主要发现
- 中位无进展生存期A组5.6个月对B组6.7个月,9个月无进展生存率A组25.1%对B组35.0%(p=0.322)。
- 中位总生存期A组10.3个月对B组9.7个月(p=0.094)。
- 疾病缓解率A组17.7%对B组22.6%。
- mFOLFIRINOX联合雷莫西尤单抗方案耐受良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vascular endothelial growth factor receptor (VEGFR)-mediated signalling contributes to andgiogenesis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Ramucirumab (RAM) is a VEGFR2 monoclonal antibody. We conducted a randomised phase II trial to compare progression-free survival (PFS) between mFOLFIRINOX with or without RAM in first line therapy of metastatic PDAC. METHODS: This phase II randomised, multi-centre, placebo controlled, double-blinded, trial randomly assigned to recurrent/metastatic PDAC patients to either mFOLFIRINOX/RAM (Arm A) or mFOLFIRINOX/placebo (Arm B). The primary endpoint is PFS at 9 months, and the secondary endpoints include overall survival (OS), response rate and toxicity evaluation. RESULTS: A total of 86 subjects enrolled, 82 eligible (42 in Arm A versus 40 in Arm B). The mean age was comparable (61.7 versus 63.0, respectively). Majority were White (N = 69) and males (N = 43). The median PFS was 5.6 compared to 6.7 months, for Arm A and B, respectively. At 9 months, the PFS rates were 25.1% and 35.0% for Arms A and B, respectively (p = 0.322). The median OS in Arm A was 10.3 compared to 9.7 months for Arm B (p = 0.094). The disease response rate for Arm A was 17.7% compared to Arm B of 22.6%. FOLFIRINOX/RAM combination was well tolerated. CONCLUSIONS: The addition of RAM to FOLFIRINOX did not significantly impact PFS or OS. The combination was well tolerated (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02581215).
引用
- Shaib WL, Manali R, Liu Y, et al. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Eur J Cancer. 2023. PMID: 37268519. doi:10.1016/j.ejca.2023.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。